Literature DB >> 16610768

HBV-ISS (Dynavax).

Joseph Jao-Yiu Sung1, Henry Lik-Yuen.   

Abstract

Dynavax is developing HBV-ISS (Heplisav), a vaccine based on hepatitis B virus (HB V) antigens and Dynavax' s immunostimulatory DNA sequence (ISS) ISS-1018, an adjuvant that acts as a TLR-9 agonist, for the potential prevention and treatment of HBV infection.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16610768

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  4 in total

Review 1.  A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2.

Authors:  Kannan Damodharan; Gandarvakottai Senthilkumar Arumugam; Suresh Ganesan; Mukesh Doble; Sathiah Thennarasu
Journal:  RSC Adv       Date:  2021-06-08       Impact factor: 4.036

Review 2.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 3.  Developmental biology of the innate immune response: implications for neonatal and infant vaccine development.

Authors:  Victoria Jane Philbin; Ofer Levy
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

4.  Toll-like receptors signaling contributes to immunopathogenesis of HBV infection.

Authors:  Yasuteru Kondo; Yoshiyuki Ueno; Tooru Shimosegawa
Journal:  Gastroenterol Res Pract       Date:  2011-11-29       Impact factor: 2.260
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.